16 November 2023
16 November 2023
The company has struggled this year on the back of reduced Covid-19 medication sales and is now streamlining costs.
In general, the goal of COP27 centered around adaptive measures to save those that are in danger of the effects of climate change.
Patients are required to use Kaftrio and Kalydeco together as a long-term medication to control their symptoms.
Arcellx is entitled to receive an equity investment of $200m in exchange for 3,242,542 shares of its common stock.
Astellas will acquire Propella’s lead product candidate, PRL-02, for treating prostate cancer.
T-Therapeutics plans to use the Series A funds to develop T-cell therapies for cancer and auto-immune disorders.
LENZ Therapeutics president and CEO Eef Schimmelpennink will lead the combined company.
The liquid suspension requires no preparation or refrigeration and treats bacterial infections such as rosacea and pelvic inflammatory disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs. However, the lack of validated predictive biomarkers of PD progression have made the development of DMTs and neuroprotective agents challenging.
Give your business an edge with our leading industry insights.
